CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record.

Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer’s disease in Italians.

Geroldi, Diego, Minoretti, Piercarlo, Bianchi, Marika, Di Vito, Clara, Reino, Marta, Bertona, Marco, Emanuele, Enzo·2005·Neuroscience Letters
DOI 10.1016/j.neulet.2005.06.014
Open this paper in CoChat — free account

Abstract

Alpha2-Heremans-Schmid glycoprotein (AHSG), also known as fetuin-A, is a highly glycosylated protein which has been recently reported to be decreased in the cerebrospinal fluid of patients with Alzheimer's disease. AHSG is genetically polymorphic and two common alleles, AHSG*1 and AHSG*2, have been described. The purpose of this study was to investigate the distribution of AHSG gene polymorphism in 235 Caucasian Italian patients with late-onset Alzheimer's disease (LOAD) and 235 age- and gender-matched healthy controls. In patients with LOAD, the genotype distribution was 184 AHSG 1*1, 44 AHSG 1*2, 7 AHSG 2*2, and was significantly different from that observed in the 235 control subjects (117 AHSG 1*1, 103 AHSG 1*2, 15 AHSG 2*2) (chi(2)=41.50, P<0.0001). After allowance for age, gender and APOE epsilon4 status, multivariate logistic regression analysis revealed that the adjusted odds ratio for the development of LOAD in AHSG 1*1 homozygotes was 3.90 (95% CI: 2.58-5.90, P<0.0001). These results suggest that the AHSG gene polymorphism may be associated with LOAD in Italians. Additional studies are warranted to examine the biological relevance of AHSG in the pathophysiology of neurodegenerative disorders.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neulet.2005.06.014

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 17

  1. Ashford, 2004, APOE genotype effects on Alzheimer's disease onset and epidemiology, J. Mol. Neurosci., 23, 157, 10.1385/JMN:23:3:157 · DOI
  2. Banine, 2000, Positive and negative elements modulate the promoter of the human liver-specific alpha2-HS-glycoprotein gene, Eur. J. Biochem., 267, 1214, 10.1046/j.1432-1327.2000.01119.x · DOI
  3. Cockrell, 1988, Mini-Mental State Examination (MMSE), Psychopharmacol. Bull., 24, 689
  4. Cox, 1986, Genetic polymorphism of alpha 2HS-glycoprotein, Am. J. Hum. Genet., 38, 699
  5. Demetriou, 1996, Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist, J. Biol. Chem., 271, 12755, 10.1074/jbc.271.22.12755 · DOI
  6. Hixson, 1990, Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI, J. Lipid Res., 31, 545, 10.1016/S0022-2275(20)43176-1 · DOI · Paper page
  7. Jersmann, 2003, Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages, Clin. Sci. (Lond.), 105, 273, 10.1042/CS20030126 · DOI
  8. Kim, 2004, Association between human alpha 2-Heremans–Schmidt glycoprotein (AHSG) polymorphism and endometriosis in Korean women, Fertil. Steril., 82, 1497, 10.1016/j.fertnstert.2004.05.089 · DOI
  9. Masliah, 2001, Functional role of TGF beta in Alzheimer's disease microvascular injury: lessons from transgenic mice, Neurochem. Int., 39, 393, 10.1016/S0197-0186(01)00046-8 · DOI
  10. McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  11. Osawa, 1997, Molecular evidence for human alpha 2-HS glycoprotein (AHSG) polymorphism, Hum. Genet., 99, 18, 10.1007/s004390050302 · DOI
  12. Puchades, 2003, Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease, Brain Res. Mol. Brain. Res., 118, 140, 10.1016/j.molbrainres.2003.08.005 · DOI · Paper page
  13. Richard, 2001, Genetic susceptibility factors for Alzheimer's disease, Eur. J. Pharmacol., 412, 1, 10.1016/S0014-2999(00)00903-1 · DOI
  14. Rittenberg, 2005, Regulation of BMP-induced ectopic bone formation by AHSG, J. Orthop. Res., 23, 653, 10.1016/j.orthres.2004.11.010 · DOI
  15. Schafer, 2003, The serum protein alpha 2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification, J. Clin. Invest., 112, 357, 10.1172/JCI17202 · DOI
  16. Srinivas, 1993, Serum alpha2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level, Mol. Endocrinol., 7, 1445, 10.1210/me.7.11.1445 · DOI
  17. Szweras, 2002, Alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodelling, J. Biol. Chem., 277, 19991, 10.1074/jbc.M112234200 · DOI

Cited by

Sorted by citations

Metadata

Authors
Geroldi, D., Minoretti, P., Bianchi, M., Di Vito, C., Reino, M., Bertona, M., & Emanuele, E.
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
2005-10
Volume
386
Issue
3
Pages
176-178
ISSN
0304-3940
DOI
10.1016/j.neulet.2005.06.014
Cited by
18
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review